PPARG and hepatocellular carcinoma: For the treatment of NAFLD/NASH at high risk of CVD or HCC, statins alone or together with anti-diabetic PPAR-gamma agonist pioglitazone and other drugs, were primarily recommended for the primary or secondary prevention of CVD, in addition to cirrhosis avoidance, liver transplantation, and HCC, according to a statement from official guidelines (Athyros et al., 2017).